Jazz Pharmaceuticals plc reiterated revenue guidance for the full year 2022. The company reiterates top line revenue guidance of $3.5 billion to $3.7 billion for the year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
109.5 USD | +1.89% | -0.44% | -11.01% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.01% | 6.82B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- JAZZ Stock
- News Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals plc Reiterates Revenue Guidance for the Full Year 2022